Cargando…
Microbial factories for recombinant pharmaceuticals
Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for human use by the Food and Drug Administration (FDA) and/or by the European Medicines Agency (EMEA) are microbial cells, either bacteria or yeast. This fact indicates that despite the diverse bottlenecks and obs...
Autores principales: | Ferrer-Miralles, Neus, Domingo-Espín, Joan, Corchero, José Luis, Vázquez, Esther, Villaverde, Antonio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669800/ https://www.ncbi.nlm.nih.gov/pubmed/19317892 http://dx.doi.org/10.1186/1475-2859-8-17 |
Ejemplares similares
-
Recombinant pharmaceuticals from microbial cells: a 2015 update
por: Sanchez-Garcia, Laura, et al.
Publicado: (2016) -
Recombinant vaccines in 2022: a perspective from the cell factory
por: de Pinho Favaro, Marianna Teixeira, et al.
Publicado: (2022) -
Bacterial cell factories for recombinant protein production; expanding the catalogue
por: Ferrer-Miralles, Neus, et al.
Publicado: (2013) -
Intracellular CXCR4(+) cell targeting with T22-empowered protein-only nanoparticles
por: Unzueta, Ugutz, et al.
Publicado: (2012) -
Engineered Biological Entities for Drug Delivery and Gene Therapy: Protein Nanoparticles
por: Domingo-Espín, Joan, et al.
Publicado: (2011)